Telix Pharmaceuticals Limited (TLX) fair value analysis
Nasdaq · Updated 2026-09-07
Telix Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes diagnostic and therapeutic products based on radiopharmaceutical technology. The company operates globally with operations in multiple regions including Australia, Europe, and North America.
Valuation status
Awaiting full valuationTLX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $10.02
- Sector
- Healthcare
- 12-month range
- $7.05–$11.84
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The upper-middle quarter of its range
What our data shows for TLX
- Shares are trading in the middle of their 12-month price range of $7.05–$11.84.
- The 14-day relative strength index sits at a neutral 62.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TLX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the TLX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TLX stock undervalued?
TLX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TLX's TickrTrends verdict?
TLX is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is TLX overbought or oversold?
TLX's 14-day RSI is in neutral territory - neither overbought nor oversold.